SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study

SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells. Gliomas are the most common type of brain tumor. Oncological...

Full description

Saved in:
Bibliographic Details
Main Authors: Brzozowski Michal, Kolesnik Marcin, Michalski Aleksander, Drop Katarzyna, Polz-Dacewicz Malgorzata
Format: Article
Language:English
Published: Sciendo 2024-12-01
Series:Current Issues in Pharmacy and Medical Sciences
Subjects:
Online Access:https://doi.org/10.2478/cipms-2024-0035
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846143543997890560
author Brzozowski Michal
Kolesnik Marcin
Michalski Aleksander
Drop Katarzyna
Polz-Dacewicz Malgorzata
author_facet Brzozowski Michal
Kolesnik Marcin
Michalski Aleksander
Drop Katarzyna
Polz-Dacewicz Malgorzata
author_sort Brzozowski Michal
collection DOAJ
description SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells. Gliomas are the most common type of brain tumor. Oncological patients are at high risk of infections, including SARS-CoV-2. Moreover, their weakened immunity causes the level of antibodies after infection or vaccination to be lower than in the healthy population. Therefore, the aim of our study was to evaluate the occurrence of SARS-CoV-2 RNA in tumor tissue collected during surgery. We also tested the level of anti-SARS-CoV-2 antibodies in these patients. The obtained results indicate the tropism of the virus to tumor tissue – glioblastoma. The level of anti-SARS antibodies was higher in patients with SARS-CoV-2 RNA detected in tumour tissue.
format Article
id doaj-art-f9ea81494ff4408a88f592c841cbc7dd
institution Kabale University
issn 2300-6676
language English
publishDate 2024-12-01
publisher Sciendo
record_format Article
series Current Issues in Pharmacy and Medical Sciences
spelling doaj-art-f9ea81494ff4408a88f592c841cbc7dd2024-12-02T12:05:33ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2300-66762024-12-0137421622010.2478/cipms-2024-0035SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary studyBrzozowski Michal0Kolesnik Marcin1Michalski Aleksander2Drop Katarzyna3Polz-Dacewicz Malgorzata4Neurosurgery Department, 1st Clinical Military Hospital with Outpatient Clinic, Lublin, PolandDepartment of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, PolandNeurosurgery Department, 1st Clinical Military Hospital with Outpatient Clinic, Lublin, PolandDepartment of Language, Rhetoric and Media Law, Institute of Journalism and Management, Faculty of Social Sciences, Catholic University of Lublin John Paul II, PolandDepartment of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, PolandSARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells. Gliomas are the most common type of brain tumor. Oncological patients are at high risk of infections, including SARS-CoV-2. Moreover, their weakened immunity causes the level of antibodies after infection or vaccination to be lower than in the healthy population. Therefore, the aim of our study was to evaluate the occurrence of SARS-CoV-2 RNA in tumor tissue collected during surgery. We also tested the level of anti-SARS-CoV-2 antibodies in these patients. The obtained results indicate the tropism of the virus to tumor tissue – glioblastoma. The level of anti-SARS antibodies was higher in patients with SARS-CoV-2 RNA detected in tumour tissue.https://doi.org/10.2478/cipms-2024-0035sars-cov-2glioblastomasars-cov-2 antibodycovid-19
spellingShingle Brzozowski Michal
Kolesnik Marcin
Michalski Aleksander
Drop Katarzyna
Polz-Dacewicz Malgorzata
SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
Current Issues in Pharmacy and Medical Sciences
sars-cov-2
glioblastoma
sars-cov-2 antibody
covid-19
title SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
title_full SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
title_fullStr SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
title_full_unstemmed SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
title_short SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
title_sort sars cov 2 in tumor tissue in glioblastoma patients preliminary study
topic sars-cov-2
glioblastoma
sars-cov-2 antibody
covid-19
url https://doi.org/10.2478/cipms-2024-0035
work_keys_str_mv AT brzozowskimichal sarscov2intumortissueinglioblastomapatientspreliminarystudy
AT kolesnikmarcin sarscov2intumortissueinglioblastomapatientspreliminarystudy
AT michalskialeksander sarscov2intumortissueinglioblastomapatientspreliminarystudy
AT dropkatarzyna sarscov2intumortissueinglioblastomapatientspreliminarystudy
AT polzdacewiczmalgorzata sarscov2intumortissueinglioblastomapatientspreliminarystudy